These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36331527)

  • 1. Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2.
    Baggio C; Udompholkul P; Gambini L; Pellecchia M
    J Med Chem; 2022 Nov; 65(22):15443-15456. PubMed ID: 36331527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell.
    Gambini L; Salem AF; Udompholkul P; Tan XF; Baggio C; Shah N; Aronson A; Song J; Pellecchia M
    ACS Chem Biol; 2018 Sep; 13(9):2633-2644. PubMed ID: 30110533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates.
    Udompholkul P; Baggio C; Gambini L; Sun Y; Zhao M; Hoffman RM; Pellecchia M
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34204178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
    Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
    J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents.
    Salem AF; Gambini L; Udompholkul P; Baggio C; Pellecchia M
    Pharmaceuticals (Basel); 2020 May; 13(5):. PubMed ID: 32397624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model.
    Salem AF; Gambini L; Billet S; Sun Y; Oshiro H; Zhao M; Hoffman RM; Bhowmick NA; Pellecchia M
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33023262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
    Wykosky J; Gibo DM; Debinski W
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3208-18. PubMed ID: 18089715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A computational and laboratory approach for the investigation of interactions of peptide conjugated natural terpenes with EpHA2 receptor.
    Goncalves BG; Banerjee IA
    J Mol Model; 2023 Jun; 29(7):204. PubMed ID: 37291458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.
    Barile E; Wang S; Das SK; Noberini R; Dahl R; Stebbins JL; Pasquale EB; Fisher PB; Pellecchia M
    ChemMedChem; 2014 Jul; 9(7):1403-12. PubMed ID: 24677792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging strategies for EphA2 receptor targeting for cancer therapeutics.
    Tandon M; Vemula SV; Mittal SK
    Expert Opin Ther Targets; 2011 Jan; 15(1):31-51. PubMed ID: 21142802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
    Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
    J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.
    Wesa AK; Herrem CJ; Mandic M; Taylor JL; Vasquez C; Kawabe M; Tatsumi T; Leibowitz MS; Finke JH; Bukowski RM; Bruckheimer E; Kinch MS; Storkus WJ
    J Immunol; 2008 Dec; 181(11):7721-7. PubMed ID: 19017961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
    Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
    Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level.
    Mo J; Zhao X; Dong X; Liu T; Zhao N; Zhang D; Wang W; Zhang Y; Sun B
    Cell Oncol (Dordr); 2020 Aug; 43(4):655-667. PubMed ID: 32291572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
    Ireton RC; Chen J
    Curr Cancer Drug Targets; 2005 May; 5(3):149-57. PubMed ID: 15892616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.
    Salem AF; Wang S; Billet S; Chen JF; Udompholkul P; Gambini L; Baggio C; Tseng HR; Posadas EM; Bhowmick NA; Pellecchia M
    J Med Chem; 2018 Mar; 61(5):2052-2061. PubMed ID: 29470068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
    Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
    Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.
    Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z
    Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.
    Wu B; Wang S; De SK; Barile E; Quinn BA; Zharkikh I; Purves A; Stebbins JL; Oshima RG; Fisher PB; Pellecchia M
    Chem Biol; 2015 Jul; 22(7):876-887. PubMed ID: 26165155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
    Chang Q; Jorgensen C; Pawson T; Hedley DW
    Br J Cancer; 2008 Oct; 99(7):1074-82. PubMed ID: 18797457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.